Related Experiment Video
Updated: Nov 8, 2025
10:25
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
5.0K
Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection
Medrxiv : the Preprint Server for Health Sciences
|April 21, 2021
Summary
New statistical methods estimate COVID-19 vaccine effectiveness against asymptomatic SARS-CoV-2 infection. These methods account for waning immunity and varying transmission rates.
Area of Science:
- Epidemiology
- Biostatistics
- Immunology
Background:
- Evaluating COVID-19 vaccine efficacy against asymptomatic SARS-CoV-2 infection is challenging due to indirect observation of infection.
- Factors like changing community transmission, staggered enrollment, and participant crossover complicate efficacy assessments.
Approach:
- Developed valid and efficient statistical methods to estimate vaccine efficacy against infection.
- Methods accommodate time-varying community transmission, staggered enrollment, and blinded/unblinded crossover.
- Utilized blood or nasal samples for periodic assessment of infection.
Key Points:
- The methods allow for estimation of potentially waning vaccine efficacy.
- Numerical studies mimicking real-world trials (BNT162b2, Prevent COVID U) validated the approach.
- Assessed the impact of crossover and diagnostic test frequency on estimate precision.
Conclusions:
- The study provides a framework for estimating COVID-19 vaccine efficacy against SARS-CoV-2 infection.
- Applicable to clinical trials with staggered enrollment and participant crossover.
- Enables better understanding of vaccine-induced protection beyond symptomatic disease.
